InVivo Therapeutics Corporation Awarded $244K Therapeutic Discovery Project Grant

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has been awarded $244,000 in grant funding as part of the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program. Proceeds from the grant will be used to support ongoing research and development costs associated with InVivo’s lead product candidate, a novel biocompatible polymer scaffolding device designed for implantation into a lesion to treat acute open-wound SCI.